TCOV
ALXN

Trust Company of Vermont’s Alexion Pharmaceuticals ALXN Stock Holding History

Trust Company of Vermont’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-26
Closed -$4K – 809
2021
Q1 		$4K Buy
+26
New +$4.02K ﹤0.01% 695
2019
Q3 		– Sell
-19
Closed -$2K – 1061
2019
Q2 		$2K Hold
19
– – ﹤0.01% 979
2019
Q1 		$3K Buy
+19
New +$2.36K ﹤0.01% 885
2017
Q1 		– Sell
-11
Closed -$1K – 950
2016
Q4 		$1K Buy
+11
New +$1.35K ﹤0.01% 904

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Trust Company of Vermont's ALXN Position: Q2 2021 in Review

Trust Company of Vermont sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 26 shares — an estimated $4K sold.

Trust Company of Vermont first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $4K in Q1 2021. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Trust Company of Vermont reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Trust Company of Vermont sold 26 Alexion Pharmaceuticals shares in Q2 2021, an estimated $4K.
  • Trust Company of Vermont first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Trust Company of Vermont's Alexion Pharmaceuticals position peaked at $4K in Q1 2021.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Trust Company of Vermont's 13F filing for Q2 2021, filed 15 Jul 2021.